{
    "nct_id": "NCT04533451",
    "official_title": "Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)",
    "inclusion_criteria": "* Documentation of Disease: Histologic or cytologic diagnosis of non-small cell lung cancer (adenocarcinoma). Stage IV or recurrent metastatic non-small cell lung cancer. No planned initiation of definitive (potentially curative) concurrent chemo-radiation\n* Planning to begin MK-3475 (pembrolizumab) treatment within 14 days of registration, with or without combination chemotherapy. Treating physician considers pembrolizumab as appropriate and plans to proceed with one of the following treatment schedules:\n\n  * MK-3475 (pembrolizumab) 200 mg IV flat dose every 21 days or 400 mg IV every 42 days.\n  * MK-3475 (pembrolizumab) 200 mg IV or 400 mg IV + carboplatin area under the curve (AUC) = 5 + pemetrexed 500 mg/m^2 (20% chemotherapy dose reduction is permitted per the discretion of the treating physician)\n* Patients will be ineligible if they have an autoimmune disorder, are post-organ transplantation, or are receiving ongoing immunosuppression treatment\n* Prior adjuvant therapy is allowed and must have been completed at least 6 months prior to registration\n* No planned radiation or other cancer treatment in the 3 months following registration\n* No untreated brain metastases. Patients must be off corticosteroids and asymptomatic at registration\n* Absolute neutrophil count (ANC) >= 1500/mm^3 (1.5 x 10^9/L)\n* Platelet count: >= 100,000/mm^3 (100 x 10^9/L)\n* Creatinine >= 30 mL/min* for patients enrolled to pembrolizumab alone and > 45 mL/min for patients enrolled to chemotherapy + pembrolizumab\n\n  * Calculated using the Cockcroft-Gault formula\n* Total serum bilirubin =< 1.5 upper limit of normal (ULN) (< 3 ULN if Gilbert's disease)\n* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN if liver metastases present)\n* Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN if bone or liver metastases present) Language: Patients must be able to speak and comprehend English in order to complete the mandatory patient-completed measures\nHealthy volunteers allowed\nMust have minimum age of 70 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}